

Modern Slavery and Human Trafficking Statement

December 2022



Table of contents

- 01 Message from our CEO
- 02 Introduction
- 02 Reporting entities
- 03 Structure, operations and supply chains
- 06 Modern slavery framework
- 07 Assessing the risks of modern slavery practices in ResMed's operations and supply chains
- 08 Actions taken by ResMed to assess and address modern slavery risks, including due diligence and remediation processes
- 12 Assessing the effectiveness of actions taken to address modern slavery risks
- 14 Consultation across ResMed
- 15 Moving forward
- 16 Mandatory criteria



Message from our CEO



ResMed is dedicated to conducting our business with the highest standards of business ethics. We have an obligation to our employees, shareholders, customers, suppliers, community representatives, and beyond to be honest, fair, and forthright in all our business activities. This includes identifying and addressing modern slavery risks as well as maintaining responsible and transparent supply chains.

ResMed's mission is to help people sleep better, breathe better, and live healthier, higher-quality lives outside the hospital. In the last 12 months, our global team has helped change over 144 million lives with our digital health products and cloud-based software solutions; our ambitious goal is to improve 250 million lives in out-of-hospital healthcare in 2025.

ResMed's overall strategy is grounded in the people who work with us, ethical business practices, and operational excellence. These foundations enable us to save and enrich hundreds of millions of lives around the world. An essential part of our ethical business practices and operational excellence is the ResMed corporate culture and our rigorous code of values and ethics. Legal compliance and an emphasis on safety and human rights of the people who work with ResMed, including those in our global supply chain as well as our business partners and contractors, are all integral elements of our global ResMed culture.

We seek the best people from around the world who are passionate about our field, and we support them to be the absolute best they can be. We understand that people – our ResMed team, our suppliers, our partners in healthcare delivery, our distributors, and patients – all need an environment and culture that encourages and promotes the best outcomes.

Given the diversity and breadth of our products, solutions and markets we operate in, we acknowledge that there may be modern slavery risks in our supply chain. We also acknowledge that to be successful in reducing these risks, we need to build upon our work from previous years. That's why in 2022 we have taken a risk-based approach, focusing on enhancing the measures we have already taken in relation to the following four key areas which you will see throughout this statement:

1. Policy enhancement
2. Upskilling employees
3. Improving our approach to identifying supply chain risks
4. Our investment in internal and external personnel and resources to progress the measures that we are taking to address and ultimately to eliminate modern slavery

This risk-based approach will enable us to continue to assess and improve our efforts over the coming years.

We are proud of ResMed's efforts to fight against modern slavery as well as our passionate social contributions directly to the communities that we serve worldwide. We are fully committed to reducing the risk of modern slavery in our business and supply chains, and we expect the same high standards from all our suppliers, contractors, and business partners.

Yours sincerely,

A handwritten signature in black ink that reads "Mick Farrell".

Mick Farrell, CEO, ResMed
December 2022



Introduction

The United Kingdom's *Modern Slavery Act 2015* ("UK Modern Slavery Act") and Australian *Modern Slavery Act 2018* (Cth) ("Australian Modern Slavery Act") require certain reporting entities to publish information describing their actions to assess and address modern slavery risks.

This statement describes the steps taken by our below reporting entities to assess and address the risks of modern slavery and human trafficking ("modern slavery") in our business and in our supply chains. This statement reflects the actions we are taking or have taken under our broader Environmental, Social and Governance ("ESG") framework.

This statement has been prepared in respect of the financial year ending 30 June 2022. It has been prepared in consultation with our key teams that collaborate to deliver our broader ESG framework and in key business areas of our reporting entities, such as procurement, legal and risk.

Our reporting entities

This statement is made by ResMed (UK) Limited (Reg. No. 2863553) ("ResMed UK") pursuant to the UK Modern Slavery Act.

This statement is a joint statement in respect of the following reporting entities within the global ResMed Group pursuant to the Australian Modern Slavery Act:

- ResMed Holdings Pty Ltd (ACN 003 765 133);
- ResMed Pty Ltd (ACN 003 765 142); and
- ResMed Asia Pacific Limited (ACN 070 076 470), (collectively "ResMed Australia").

Together these reporting entities are referred to as ResMed ("we," "us," or "our").

Our structure, operations and supply chains

Structure

ResMed Inc., a Delaware corporation, is the ultimate holding entity for the ResMed group of companies, including ResMed Australia and ResMed UK (“ResMed Group”). ResMed Inc’s principal share listing is on the New York Stock Exchange; its secondary listing of common stock via Chess Depositary Instruments is available on the Australian Securities Exchange.

ResMed Australia comprises three reporting entities pursuant to the Australian Modern Slavery Act that:

- are Australian companies limited by shares;
- employ together, either directly or through subsidiaries, approximately 1,360 people in Australia; and,
- have their registered offices at 1 Elizabeth Macarthur Drive, Bella Vista, NSW, 2153, Australia.

ResMed UK

- is a United Kingdom company limited by shares;
- employs approximately 110 people in the United Kingdom; and,
- has its registered office at Quad 1, First Floor, Becquerel Avenue, Harwell Campus, Didcot, Oxfordshire, OX11 0RA, United Kingdom.

Operations

The ResMed Group is a global leader in digital health and cloud connected medical devices. We design innovative solutions to treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. The ResMed Group’s digital health technologies and cloud connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease (“COPD”), and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, our products improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems. The ResMed Group markets its products in more than 140 countries.

ResMed Australia’s main operations primarily include manufacturing, engineering, research and development, sales, and administration. ResMed UK’s operations are primarily sales and distribution.

Our primary research and development facility is in Sydney, Australia. The ResMed Group also conducts research and development in Singapore, Ireland, China, Canada, Malaysia, and the United States of America. Main manufacturing sites are located in: Singapore; Australia; United States of America; Malaysia; and China.

As part of a globally distributed manufacturing network our aim is to optimize quality, cost control, time to market for new product introduction, and supply chain resilience. Manufacturing operations consist of specialist component production as well as assembly and testing of our devices, masks, and accessories.



Our people

As of 30 June 2022, the ResMed Group had approximately 8,160 employees or contingent workers, of which approximately 3,480 were employed in cost of sales activities including areas such as warehousing and manufacturing, 1,350 in research and development and 3,330 in sales, marketing and administration. Of the ResMed Group's employees and contingent workers, approximately 3,020 (37%) were located in the United States, Canada and Latin America, 2,370 (29%) in Asia, 1,360 (17%) in Australia and 1,410 (17%) in Europe.

We believe maintaining a physically safe and mentally healthy working environment is essential in supporting our people to deliver their best work. We rely on global standards to provide the framework for our locally compliant, integrated and effective health and safety management systems which enable the capability, autonomy and accountability of the leaders to manage local sites. Our approach is to place health and safety as a positive contributor to innovation, continuous improvement and business sustainability through focusing on making work easier, which in turn makes work safer and more efficient.

As the COVID-19 pandemic spread, we implemented and maintained significant changes that we determined were in the best interest of our employees. These included work-from-home flexibility, adjusted attendance policies and additional safety measures for our on-site workforce. We have since re-opened most offices, consistent with local public health guidance and protocols, and continue to support flexible working globally.

Supply chain

Our suppliers are critical partners in the operation and success of our business, and we expect them to adopt our standards with respect to modern slavery. We communicate these expectations regarding modern slavery through our systems, policies, contracts, and procedures.



The 10 countries in which we have the most mapped sites for direct suppliers of components and materials are shown above. ResMed UK sources most of its products from related ResMed entities. We discuss high risk factors, geographies, and sectors in our ‘assessment of risks of modern slavery practices’ section on page 7.

Of the numerous raw materials, parts, and components purchased for assembly of our therapeutic and diagnostic sleep disorder products, many are available from multiple vendors. We also purchase uniquely configured components from various suppliers, including some who are single-source suppliers for us. We generally manufacture to our internal sales forecasts and fill orders as received.

The COVID-19 pandemic has continued to impact the global supply chain, primarily through constraints on raw materials and electronic components, including semiconductor chips. These constraints have impacted and may continue to impact the ResMed Group’s ability to manufacture products in quantities necessary to satisfy customer demand. We have observed a reduction in both inbound and outbound transportation capacity as a result of port closures and delays associated with the pandemic, which is causing longer lead times in receiving raw materials into and distributing finished goods out of our manufacturing facilities, as well as increased freight costs. We are actively working to mitigate the impact of the widespread supply chain and logistics issues.

Our modern slavery framework

Following the measures we have taken and continue to take with respect to addressing all of our modern slavery commitments, we have developed a framework in order to classify our efforts into a common structure. This framework also allows us to ensure that our efforts are spread over targeted key areas, namely: Governance; Risk assessment; Due diligence; Grievance and remediation; Training; and Monitoring and reporting.

As our CEO explains in the opening message to this statement, we are taking a risk-based approach to our commitments and this year we have focused on enhancing and improving measures that we have already taken in relation to enhancing policies, upskilling staff, risk assessment and investment in internal and external personnel and resources.

The bullet points below give a snapshot of these enhancements in the context of our modern slavery framework.



Monitoring and reporting

- Annual modern slavery statements
- Annual self-reflection
- 3rd party monitoring of suppliers
- 3rd party feedback



Governance

- ResMed Code of Business Conduct and Ethics
- Global Third Party Code of Conduct
- Whistleblower Policy
- Global Procurement Policy



Embedding training

- Modern slavery training
- Governance policy training
- Informal modern slavery awareness sessions



Risk assessment

- Mapped and segmented supply chain
- Annual risk questionnaires
- Desktop reviews



Grievance and remediation

- Ethics Hotline



Due diligence

- AME verification
- Desktop review
- Risk questionnaires

Our assessment of the risks of modern slavery practices in ResMed's operations and supply chains

ResMed continues its due diligence of its third-party suppliers by consulting third-party classifications of high-risk factors, sectors, and geographies, such as the Global Slavery Index, to inform our modern slavery exposure profile. ResMed also continues to invest in third-party monitoring tools to identify high-risk factors, sectors, and geographies relevant to our operations and supply chain because the risks for modern slavery are constantly changing.

As in previous years, we continue to assess the factors, sectors, and geographies shown to *the right* as having a heightened risk to potentially cause, contribute to, or directly link ResMed's operations or supply chains to instances of modern slavery.

ResMed's close working relationships with its Tier 1 Suppliers provides ResMed with visibility to assess the risks of modern slavery in its supply chain. However, we continue to acknowledge and are aware that there are high risk factors and sectors within our broader supply chain that may pose higher risks of modern slavery. A "Tier 1 Supplier" is a supplier with whom ResMed has a direct relationship. We describe below the further actions we have taken to respond to and mitigate these risks.

Our commitment to addressing modern slavery and reducing our risk exposure to modern slavery practices in our operations and supply chains is ongoing, and we remain dedicated to continuing to make improvements with respect to our supply chain procurement systems and processes in years to come.



High risk factors

- Labour-intensive services
- Outsourced labour hire
- Raw materials sourcing
- Migrant workers



High risk sectors

- Cleaning and maintenance services
- Electronics
- Manufacturing
- Information technology
- Logistics, transport
- Packaging (paper)



High risk geographies

- China
- Indonesia
- Malaysia
- Thailand



Our actions to assess and address modern slavery risks, including due diligence and remediation processes

Identifying and assessing risks

Over the last year, we continued using the existing solutions that were introduced in prior reporting periods and strengthened the actions we take to assess our modern slavery risks through a risk-based approach focusing on onboarding suppliers, monitoring suppliers, improvements to our annual supplier questionnaire, and gap analyses. Details of our key tools and actions during the reporting period are set out below:

Verifying new suppliers

Key tools

Verifying new suppliers using a third-party analytics intelligence platform for economic sanctions and Adverse Media Events (“AME”) relating to social responsibility including human rights, discrimination, workforce disputes, and health and safety issues.

Actions during reporting period

Successfully launching a new supplier onboarding platform to streamline our existing processes and enhance record keeping, which systematically incorporates risk-based due diligence including AME checks.

Monitoring existing suppliers

Key tools

Monitoring existing suppliers using a third-party analytics intelligence platform for economic sanctions and AMEs relating to social responsibility including human rights, discrimination, workforce disputes, and health and safety issues.

Actions during reporting period

During the reporting period, we identified potential gaps in the data we receive from our existing third-party supply chain monitoring solutions. As a result, we are evaluating opportunities to improve how we monitor our supply chain.

Annual questionnaires

Key tools

Issuing annual risk questionnaires to select suppliers, tracking completion, and following up for additional information if necessary.

Actions during reporting period

Updating our annual supplier risk questionnaire that we issue to key suppliers in order to help us better assess the risks of modern slavery in our supply chain.

Mapping and monitoring our supplier network

Key tools

Mapping and monitoring our manufacturing supplier network in real time using a third-party artificial intelligence machine learning platform to identify events that may indicate risks of modern slavery.

Actions during reporting period

As a result of identifying potential gaps in the data we receive from our existing third-party supply chain mapping and monitoring solutions, we are evaluating opportunities to improve how we map and monitor our supply chain.

We also began segmenting our supply base with a new approach that we plan to roll out in future reporting periods. This will enable us to better segment, filter and map our supply base against key risk indicators and perform risk-based desktop analyses.

Addressing risks

ResMed is committed to reducing the risks of modern slavery occurring in our supply chains and in any part of our business.

Over the last year, we continued our existing actions from prior reporting periods, and enhanced our actions, to address risks of modern slavery, focusing on upskilling our employees through awareness, training, and policy enhancements. Details of our key tools and actions during the reporting period are set out below:

Internally facing actions

Code of Business Conduct and Ethics

Key tools

Our Code of Business Conduct and Ethics, which applies to all ResMed employees globally (“Ethics Code”), contains provisions to protect employees’ freedom of association and right to work in a harassment-free work environment.

The Ethics Code requires all employees to: uphold ResMed’s corporate values; comply with all applicable laws and regulations; and, report any known or suspected violations via the Ethics Hotline. Failure to comply with the Ethics Code may result in disciplinary action up to and including termination of employment.

Actions during reporting period

We require our employees to complete regular Ethics Code training.

In the three-month period ending 30 June 2022 approximately 90% of designated Ethics Code training was completed in the requisite time period.

Whistleblower Policy

Key tools

ResMed Australia has a Whistleblower Policy which allows for employees, suppliers and workers of suppliers (amongst others) to raise issues with ResMed directly.

ResMed encourages its employees and other relevant disclosers to feel confident about raising their concerns by being able to access a reporting and investigative mechanism that is objective and confidential, where they know that they are protected from reprisal for doing so. Employees and other relevant disclosers can make their reports to any eligible recipient, as well as via the Ethics Hotline. ResMed’s Ethics Hotline is managed by an independent third party, is accessible 24 hours a day, seven days a week, with translators available when necessary.

Actions during reporting period

We began updating ResMed Australia’s Whistleblower Policy as part of a periodic review and developing a training strategy (completed in FY23).

Ethics Hotline

Key tools

ResMed's Ethics Hotline is managed by an independent third party, is accessible 24 hours a day, seven days a week, with translators available when necessary. A breach or suspected breach of ResMed policies should be reported via the Ethics Hotline.

Actions during reporting period

We monitor the Ethics Hotline for reports about modern slavery. None were received during the reporting period.

Informal training and awareness

Key tools

Ongoing risk-based training and awareness initiatives to relevant employees about the risks of modern slavery.

Actions during reporting period

Continually enhancing our procurement, legal, director and senior management teams' knowledge about modern slavery risks, ethical sourcing, and human rights as they relate to ResMed's operations and supply chain through regular informal updates by our internal subject matter experts.

Global Procurement Policy

New approaches

Launching a new internal Global Procurement Policy that applies to all ResMed employees and expressly requires ResMed's procurement activities to meet ResMed's expectation that suppliers disclose information to support our public statements on modern slavery. The Global Procurement Policy also expressly requires use in conjunction with the ResMed Global Third Party Code of Conduct, which expressly prohibits modern slavery as described above.

Actions during reporting period

We require employees to review and acknowledge the Global Procurement Policy.

All employees have a duty (which has been acknowledged) under the Global Procurement Policy to report known or suspected breaches of this Policy through their manager, our People team, or the Ethics Hotline.

Mandatory training

New approaches

Successfully introducing a pilot training module about modern slavery, from a third-party subject matter expert.

Actions during reporting period

We made this training mandatory for certain employees using a risk-based approach.

Over 90% of this training was completed in the requisite time period.

We also made this material available to all employees on our online learning management system.

Externally facing actions

We have also continued to enhance our work with our third parties to ensure that we receive the appropriate information that we require from them in order to assess the risk of modern slavery in our supply chains. Details of our key tools and actions during the reporting period are set out below:

Global Third Party Code of Conduct

Key tools

The Global Third Party Code of Conduct, which replaced and strengthened the existing Supplier Code of Conduct during the prior reporting period. ResMed's Global Third Party Code of Conduct sets out ResMed's expectations for distributors, business partners, suppliers, advisors, and other third parties registering, promoting, selling, and marketing ResMed products and services, or otherwise interacting with government officials, health care professionals, or others on ResMed's behalf. It clearly sets out our expectation of our Tier 1 Suppliers to comply with a range of modern slavery laws, and expressly prohibits slavery in any of ResMed's suppliers' supply chains, or in any part of their business. Suspected, or known, violations of the code can be reported via the Ethics Hotline.

Actions during reporting period

After introducing the strengthened Global Third Party Code of Conduct in FY21, in the FY22 reporting period we took further steps by requiring the key suppliers that receive our annual supplier risk questionnaire to also acknowledge ResMed's Global Third Party Code of Conduct.

Supplier Manual

Key tools

The Supplier Manual, which requires suppliers to comply with labour and employment laws, including prohibitions against child labour, and forced or involuntary labour, and requests suppliers to acknowledge that they comply with the United Kingdom's Modern Slavery Act and the Australian Modern Slavery Act. ResMed takes failure to comply with any part of the Supplier Manual seriously and may take consequential actions including removal of suppliers from ResMed's approved supplier list in the event of non-compliance with any part of the Supplier Manual.

Actions during reporting period

During the reporting period we made updates to the Supplier Manual and sent it to key suppliers. We also continue providing this to suppliers during onboarding. We did not receive any reports of modern slavery from our suppliers during the reporting period.

Standard Supply Terms

Key tools

Standard Supply Terms, which prohibit suppliers from using child labour, prison labour, slave labour, or any other form of forced or involuntary labour; require suppliers to comply with applicable laws relating to wages, hours and conditions of employment, and occupational health and safety; and to expect and require the same from their sub-contractors.

Actions during reporting period

Engaging an independent third-party subject matter expert to review our existing clauses that address modern slavery and developing a clause library to empower our internal legal team to take a risk-based approach in selecting appropriate clauses to address modern slavery when negotiating contracts with third parties.

Assessing the effectiveness of actions taken to address modern slavery risks

We continue making conscious and considered steps to enhance our systems and processes for mitigating modern slavery risks. We appreciate that this is a continuous journey to which we are committed.

In this section we have summarized key actions arising out of our four FY22 focus areas, and assessed each action through the below Effectiveness Indicators that we developed with reference to publicly available guidance, information and analyses.

Legend of Effectiveness Indicators

- 1 Setting up a process for regular review, internal engagement, or feedback
- 2 Greater internal awareness, training and investment
- 3 Partnering with a third party
- 4 Updating our assessment process and considering trends
- 5 Conducting internal audits or monitoring of specific steps to assess and address risks
- 6 Tracking actions

Focus area	Our actions this reporting period	Effectiveness indicator
Training	<ul style="list-style-type: none"> • Purchased eLearning modules and began rolling them out as mandatory internal trainings • Grew the breadth and depth of informal awareness about responding to modern slavery risks 	2

Focus area	Our actions this reporting period	Effectiveness indicator
Policy	<ul style="list-style-type: none"> Introduced the requirement for key suppliers to acknowledge our Third Party Code of Conduct 	2
	<ul style="list-style-type: none"> Developed a modern slavery clause library through a global partner 	3
Assessing Risk	<ul style="list-style-type: none"> Undertook a review of our existing process and capability for assessing the risks of modern slavery within our supply chain Began developing a new model for assessing the risks of modern slavery within our supply chain in consultation with other entities in the ResMed Group 	4
	<ul style="list-style-type: none"> Continuously improving our ways of assessing risk and making changes based on data trends, for example identifying the need for better supply chain monitoring solutions and beginning a new supply chain risk assessment initiative 	4
	<ul style="list-style-type: none"> Reviewing adequacy of current supply chain monitoring data and identifying potential gaps. Seeking to address those gaps through an evaluation of multiple supply chain monitoring solutions and beginning a new supply chain risk assessment framework 	5
Investment in internal and external resourcing	<ul style="list-style-type: none"> Ongoing consultation within our organization in preparation of this statement and stakeholder reviews of our actions 	1
	<ul style="list-style-type: none"> Public disclosure of progress on past, present, and future focus areas 	6
	<ul style="list-style-type: none"> Upskilling and increasing the number of people in our legal team that focus on ESG matters 	2
	<ul style="list-style-type: none"> Re-evaluating our third-party supply chain monitoring and mapping solutions to enhance our detection and assessment capabilities by identifying and interviewing a leading supply chain sustainability management solution provider 	2

Consultation across ResMed

Each of the ResMed reporting entities have consulted with each other in preparing this joint statement. In preparing this statement, ResMed Australia also consulted with representatives of the entities that it owns or controls, that have material operations, to assess their retrospective efforts and future plans for reducing modern slavery risks.

Throughout the reporting period	After the reporting period	Preparing this statement
<p>Subject matter experts from internal legal and procurement teams met regularly with applicable senior management to continue raising awareness about modern slavery, regulatory trends, and evolving social expectations that may be relevant to our business.</p>	<p>During our recent global procurement leadership team strategy workshop, we had a dedicated session to raise awareness about modern slavery, regulatory developments, and our ongoing efforts to respond to modern slavery risks. This workshop resulted in requests from our procurement leadership team for additional training, which is now underway.</p>	<p>In preparation of this statement our internal legal and procurement subject matter experts met with directors of each reporting entity to reflect on the FY22 reporting period, our actions, this report, and opportunities to improve in future reporting periods.</p>

As a result of our modern slavery program maturing, we are making efforts to consult broadly across all levels of our organization throughout the reporting period as set out above because we believe this ongoing dialogue will have a compounding effect. We are proud of the keen interest and efforts of our employees to address the risk of modern slavery.

Moving forward

We are committed to continuously improving our efforts to address the challenging issues related to modern slavery. ResMed has established the foundations of our due diligence processes, is monitoring evolving events relating to modern slavery with risk-based systems and continues to have open dialogue with our supplier network. We will continue monitoring the effectiveness of our approach in addressing the risks of modern slavery and continue to update and develop our systems as appropriate.

Following our review of the effectiveness of the steps we have taken this past financial year ending 30 June 2022, we are focusing on the following further steps to reduce the risk of modern slavery in our operations and supply chains, over future reporting periods:

Focus area	Category
Enhancing our internal modern slavery training program, including tailored training in some higher risk regions	Addressing
Implementing new approaches to deepen the impact of ResMed's policies and expectations of suppliers to respond to slavery risks	Addressing
Refreshing our internal approach to assessing risks of modern slavery in our supply chain through new segmentation, analysis, detailed assessments and actions	Assessing
Piloting a more comprehensive risk assessment on one or more sample suppliers that we think may have heightened risk indicators of modern slavery	Assessing
Launching a high-level ESG (including modern slavery) materiality assessment and mapping of regulatory developments with an independent third-party	Assessing
Developing a modern slavery checklist that any ResMed employee can complete when visiting a supplier site	Assessing

Mandatory criteria

The following page number/s of our statement address each of the mandatory criteria in section 16 of the Australian Modern Slavery Act:

Mandatory criteria	Page number/s
Identify the reporting entity	2
Describe the reporting entity's structure, operations and supply chains	3-5
Describe the risks of modern slavery practices in the operations and supply chains of the reporting entity and any entities it owns or controls	7
Describe the actions taken by the reporting entity and any entities it owns or controls to assess and address these risks, including due diligence and remediation processes	8-12
Describe how the reporting entity assesses the effectiveness of these actions	12-13
Describe the process of consultation on the development of the statement with any entities the reporting entity owns or controls (a joint statement must also describe consultation with the entity covered by the statement)	14
Any other information that the reporting entity, or the entity giving the statement, considers relevant	1-16

This statement constitutes ResMed Australia's modern slavery statement in accordance with the Australian Modern Slavery Act 2018 (Cth) for the financial year ending 30 June 2022 and captures the activities of ResMed Australia's Australian subsidiaries.

This statement constitutes ResMed (UK) Ltd's slavery and human trafficking statement in accordance with section 54(1) of the United Kingdom Modern Slavery Act 2015 for the financial year ending 30 June 2022. This statement has been reviewed by the board of ResMed (UK) Ltd (Reg. No. 2863553) and was approved on 19 December 2022.

This statement has been reviewed and approved by the directors of ResMed Holdings Pty Ltd on 19 December 2022, in their capacity as principal governing body of ResMed (UK) Ltd (Reg. No. 2863553), ResMed Pty Ltd (ACN 003 765 142), ResMed Asia Pacific Limited (ACN 070 076 470), and ResMed Holdings Pty Ltd (ACN 003 765 133).



David Pendarvis
Chief Administrative Officer & Global General Counsel
Director of ResMed Holdings Pty Ltd and ResMed (UK) Ltd

Contact Information

For Investors InvestorRelations@ResMed.com

For Media News@ResMed.com

Investor relations <https://investor.resmed.com/investor-relations/default.aspx>

**Corporate
Governance
Documents** <https://investor.resmed.com/investor-relations/board-and-management/default.aspx?section=documents>

**Corporate
Citizenship** <https://investors.resmed.com/investor-relations/about-us/Corporate-Citizenship-at-ResMed/default.aspx>



ResMed